The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective

References

• Grodstein F, Stampfer M. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiol Dis 1995;38:199–210
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer M. Estrogen for women at varying risk of coronary disease. Maturitas 1998;30:19–26
   PubMed Web of Science ®Google Scholar
• Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Commun Health 1989;43:173–8
   PubMed Web of Science ®Google Scholar
• Falkeborn M, Persson I, Adami HO. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992;99:821–8
   PubMedGoogle Scholar
• Psaty BM, Heckbert SR, Atkins D, . The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154:1333–9
   PubMed Web of Science ®Google Scholar
• Grodstein F, Stampfer MJ, Manson JE, . Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–61
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer R, Stefanick ML, . Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404–14
   PubMed Web of Science ®Google Scholar
• Prentice RL, Langer R, Stefanick ML, . Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone therapy and cardiovascular disease. Am J Epidemiol 2006;163:589–99
   PubMed Web of Science ®Google Scholar
• Henderson BD, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151:75–8
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000;133:933–41
   PubMed Web of Science ®Google Scholar
• Hulley S, Grady D, Bush T, . Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan KB, . Effects of estrogen replacement on the progression of coronary artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Lobo RA, . Estrogen in the prevention of atherosclerosis: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939–53
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Azen SP, . Hormone therapy and the progression of coronary artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535–45
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. A window of opportunity: the reduction of coronary heart disease and total mortality with menopausal therapies is age and time dependent. Brain Res 2011;1379: 244–52
   PubMed Web of Science ®Google Scholar
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. Coronary heart disease and menopause management: the swinging pendulum of HRT. Atherosclerosis 2009;207:336–40
   PubMed Web of Science ®Google Scholar
• NHLBI stops trial of estrogen plus progestin due to increased breast cancer risk, lack of overall benefit. National Institutes of Health, NIH News Release; 9 July 2002. http://www.nhlbi.nih.gov/new//press/02–07-09.htm
   Google Scholar
• Rossouw JE, Prentice RL, Manson JE, . Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465–77
   PubMed Web of Science ®Google Scholar
• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Manson JE, Hsia J, Johnson KC, . Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523–34
   PubMed Web of Science ®Google Scholar
• Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Women's Health 2006;15:35–35
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Hsia J, Langer RD, Manson JE, . Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357–65
   PubMed Web of Science ®Google Scholar
• LaCroix AZ, Chlebowski RT, Manson JE, ., for the WHI Investigators. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with hysterectomy: a randomized controlled trial. JAMA 2011;305:1305–1305
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JME, Greyber E, Salpeter EE. Coronary heart disease events associated with hormone therapy in younger and older women: a meta-analysis. J Gen Intern Med 2006;21: 363–6
   PubMed Web of Science ®Google Scholar
• Manson JE, Allison MA, Rossouw JE, ., for the WHI and WHI-CACS Investigators. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591–2591
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Walsh JME, Greybe E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med 2004;19:791–804
   PubMed Web of Science ®Google Scholar
• Collins P, Mosca L, Geiger MJ, . Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the raloxifene use for the heart trial: results of subgroup analyses by age and other factors. Circulation 2009;119: 922–30
   PubMed Web of Science ®Google Scholar
• Cummings SR, Ensrud K, Delmas PD, ., for the PEARL Study Investigators. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010;362:686–686
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ, Kono N, ., for the WISH Research Group. Isoflavone soy protein supplementation and progression of subclinical atherosclerosis in healthy postmenopausal women: a randomized controlled trial. Stroke 2011;42:3168–3168
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Cheng J, Thabane L, Buckley NS, Salpeter EE. Bayesian meta-analysis of hormone therapy and mortality in younger postmenopausal women. Am J Med 2009;12:1016–22
   Web of Science ®Google Scholar
• Salpeter SR, Buckley NS, Liu H, Salpeter EE. The cost-effectiveness of hormone therapy in younger and older postmenopausal women. Am J Med 2009;122:42–52
   PubMed Web of Science ®Google Scholar
• Walsh JME, Pignone M. Drug treatment of hyperlipidemia in women. JAMA 2004;291:2243–52
   PubMed Web of Science ®Google Scholar
• Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with stain therapy: a meta-analysis. Int J Cardiol 2010;138:25–31
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, . The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cook NR, Lee IM, . A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–1293
   PubMed Web of Science ®Google Scholar
• Berger JS, Roncaglioni MC, . Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295: 306–13
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, . Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134–41
   PubMed Web of Science ®Google Scholar
• Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation 2010;121:1069–77
   PubMed Web of Science ®Google Scholar
• de Lorgeril M, Salen P, Abramson J, . Cholesterol lowering, cardiovascular diseases, and rosuvastatin – JUPITER controversy. Arch Intern Med 2010;170:1032–6
   PubMed Web of Science ®Google Scholar
• Kaul S, Morrissey RP, Diamond GA. By jove! What is a clinician to make of JUPITER? Arch Intern Med 2010;170:1073–7
   PubMed Web of Science ®Google Scholar
• Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–2486
   PubMed Web of Science ®Google Scholar
• Mosca L, Appel LJ, Benjamin EJ, . Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 2004;109:672–93
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clin Obstet Gynecol 2008; 51:564–80
   PubMed Web of Science ®Google Scholar
• Hodis HN, Mack WJ. Postmenopausal hormone therapy in clinical perspective. Menopause 2007;14:944–57
   PubMed Web of Science ®Google Scholar
• Hodis HN. Assessing benefits and risks of hormone therapy in 2008: new evidence, especially with regard to the heart. Cleveland Clin J Med 2008;75(Suppl 4):S3–12
   PubMedGoogle Scholar
• Stevenson JC, Hodis HN, Pickar JH, Lobo RA. HRT and breast cancer risk: a realistic perspective. Climacteric 2011;14:33–6
   Google Scholar
• Anderson GL, Chlebowski RT, Rossouw JE, . Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 2006;55: 103–15
   PubMed Web of Science ®Google Scholar
• Heiss G, Wallace R, Anderson GL, ., for the WHI Investigators. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036–1036
   PubMed Web of Science ®Google Scholar
• Stefanick ML, Anderson GL, Margolis KL, ., for the WHI Investigators. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 2006;295:1647–1647
   PubMed Web of Science ®Google Scholar
• Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen replacement therapy after ischemic stroke. N Engl J Med 2001;345:1243–9
   PubMed Web of Science ®Google Scholar
• Simon JA, Hsia J, Cauley JA, ., for the HERS Research Group. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). Circulation 2001;103:638–638
   PubMed Web of Science ®Google Scholar
• Wassertheil-Smoller S, Hendrix SL, ., for the WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673–2673
   PubMed Web of Science ®Google Scholar
• Cushman M, Kuller LH, Prentice R, ., for the Women's Health Initiative Investigators. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573–1573
   PubMed Web of Science ®Google Scholar
• Curb JD, Prentice RL, Bray PF, . Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772–80
   PubMed Web of Science ®Google Scholar
• Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006;295:74–80
   PubMed Web of Science ®Google Scholar
• Bonovas S, Filioussi K, Tsavaris N, Sitaras NM. Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 2005;23:8606–12
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267–78
   PubMed Web of Science ®Google Scholar
• Margolis KL, Bonds DE, Rodabough RJ, ., for the Women's Health Initiative Investigators. Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative hormone trial. Diabetologia 2004;47:1175–1175
   PubMed Web of Science ®Google Scholar
• Kanaya AM, Herrington D, Vettinghoff E, . Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. Ann Intern Med 2003; 138:1–9
   PubMed Web of Science ®Google Scholar
• Bonds DE, Lasser N, Qi L, . The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomized trial. Diabetologia 2006;49:459–68
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, . Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet 2010;375:735–42
   PubMed Web of Science ®Google Scholar
• Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-analysis. Diabetes Care 2009;32:1924–9
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SRK, Welsh P, . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011;305:2556–2556
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, . Statin use and risk of diabetes mellitus in postmenopausal woman in the Women's Health Initiative. Arch Intern Med 2012, Jan 9. Epub ahead of print
   Google Scholar
• Nelson HD, Vesco KK, Haney E, . Nonhumoral therapies for menopausal hot flashes: systematic review and meta-analysis. JAMA 2006;295:2057–71
   PubMed Web of Science ®Google Scholar
• The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549–59
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleight P, Peto R, for the Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–67
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw GJ, Murphy MB, ., on behalf of the PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002;360:1623–1623
   PubMed Web of Science ®Google Scholar
• The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849–61
   PubMed Web of Science ®Google Scholar
• DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: randomised controlled trial. Lancet 2006;368:1096–105
   PubMed Web of Science ®Google Scholar
• Home PD, Pocock SJ, Beck-Nielsen H, ., for the RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomized, open-label trial. Lancet 2009;373: 2125–2125
   PubMed Web of Science ®Google Scholar
• Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009;180:32–9
   PubMed Web of Science ®Google Scholar
• Dormandy J, Bhattacharya M, de Bruyn ART, on behalf of the PROactive investigators. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Safety 2009;32: 187–202
   PubMed Web of Science ®Google Scholar
• Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM. Use of alendronate and risk of incident atrial fibrillation in women. Arch Intern Med 2008;168:826–31
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R, ., for the HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356:1809–1809
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364;1728–37
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Barber PA, Doughty RN, . Vascular events in healthy older women receiving calcium supplementation: randomized controlled trial. BMJ 2008;336:262–6
   PubMed Web of Science ®Google Scholar
• Omenn GS, Goodman GE, Thornquist MD, . Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–5
   PubMed Web of Science ®Google Scholar
• Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med 1989;321:129–35
   PubMed Web of Science ®Google Scholar
• Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, . Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010;304:411–18
   PubMed Web of Science ®Google Scholar
• Bolland MJ, Avenell A, Baron JA, . Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010;341:c3691
   PubMed Web of Science ®Google Scholar